Bifunctional nucleoside hydrogel, preparation method therefor and use thereof

Patent metadata

Field	Value
Publication number	US-12268778-B2
Application number	US-201917594657-A
Country	US
Kind code	B2
Filing date	May 31, 2019
Priority date	Apr 25, 2019
Publication date	Apr 8, 2025
Grant date	Apr 8, 2025

Abstract

A bifunctional nucleoside hydrogel is formed by dissolving isoguanosine, guanosine and a borate in water or an aqueous solution and then crosslinking same. The bifunctional nucleoside hydrogel integrates a carrier and a drug effect and has a significant inhibitory effect on the activity of tumor cells, and in particular has a significant inhibitory effect on the activity of cells related to lung cancer, glioma, osteoma, colon cancer, breast cancer, oral squamous cell carcinoma and tongue squamous cell carcinoma, of which the inhibitory effect on the activity of cells related to oral squamous cell carcinoma is the best. Therefore, the bifunctional nucleoside hydrogel has potential application prospects in preparing anti-tumor drugs, and particularly, same can provide a new approach for treating oral squamous cell carcinoma.

First claim

The invention claimed is:

1. A bifunctional nucleoside hydrogel comprising cross-linked isoguanosine, guanosine, and borate, wherein said hydrogel is formed by cross-linking of isoguanosine, guanosine and borate in water or in an aqueous solution.

2. The bifunctional nucleoside hydrogel according to claim 1 , wherein a molar ratio of isoguanosine, guanosine, and borate is 1:(1-5):(1-5).

3. The bifunctional nucleoside hydrogel according to claim 1 , wherein the aqueous solution that is obtained by dissolving isoguanosine, guanosine and borate in water or in the aqueous solution, and the concentration of isoguanosine is 0.005-5.6 wt %.

4. The bifunctional nucleoside hydrogel according to claim 1 , wherein said borate is selected from LiB(OH) 4 , NaB(OH) 4 , KB(OH) 4 , RbB(OH) 4 , CsB(OH) 4 and mixtures thereof.

5. The bifunctional nucleoside hydrogel according to claim 1 , wherein said aqueous solution is a phosphate buffer.

6. The bifunctional nucleoside hydrogel according to claim 1 , wherein said cross-linking comprising dissolving isoguanosine, guanosine, and borate in hot water or the aqueous solution, followed by cooling and cross-linking.

7. The bifunctional nucleoside hydrogel according to claim 6 , wherein the cross-linking occurs at room temperature.

8. A preparative method of the bifunctional nucleoside hydrogel according to claim 1 , comprising:
dissolving isoguanosine, guanosine and borate in water or the aqueous solution under heating, and then cooled and crosslinked.

9. The preparative method according to claim 8 , wherein isoguanosine and borate are dissolved in water or the aqueous solution under heating to form a first mixture, and is dissolved in the mixture under heating to form a second mixture, and the second mixture is gradually cooled at room temperature and crosslinks.

10. A method for treating a tumor, comprising applying an antitumor drug comprising a bifunctional nucleoside hydrogel comprising cross-linked isoguanosine, guanosine, and borate to a subject in need thereof,
wherein the tumor is selected from lung cancer, glioma, osteoma, colon cancer, breast cancer, oral squamous cell carcinoma, and tongue squamous cell carcinoma, and
wherein the bifunctional nucleoside hydrogel is formed by cross-linking of isoguanosine, guanosine and a borate selected from LiB(OH) 4 , NaB(OH) 4 , KB(OH) 4 , RbB(OH) 4 , CsB(OH) 4 , and mixtures thereof.

11. The method according to claim 10 , wherein a molar ratio of isoguanosine, guanosine, and borate of the bifunctional nucleoside hydrogel is 1:(1-5):(1-5).

12. The method according to claim 11 , wherein the molar ratio of isoguanosine, guaniosine, and borate is 1:1:1.

13. The method according to claim 10 , wherein the bifunctional nucleoside hydrogel is prepared by a preparation method comprising:
dissolving isoguanosine, guanosine, and the borate in water or in an aqueous solution at an elevated temperature to form a reaction mixture; and
cooling the reaction mixture.

14. The method according to claim 13 , wherein the reaction mixture comprises 0.005-5.6 wt % of isoguanosine.

15. The method according to claim 14 , wherein the reaction mixture comprises 0.3-5.6 wt % of isoguanosine.

16. The method according to claim 13 , wherein the aqueous solution is a phosphate buffer.

17. The method according to claim 10 , wherein the tumor is oral squamous cell carcinoma or tongue squamous cell carcinoma.

Assignees

• Univ Sichuan

Inventors

• Zhao Hang
• Zeng Xin
• Ji Ning
• Feng Hui
• Liu Jiang
• Chen Qianming

Classifications

• C07H23/00

  Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12 (esters with inorganic acids C07H11/00) · CPC title

• A61K47/24

  containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61K9/06 Primary

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title